Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis
Authors
Keywords
-
Journal
BMC Pharmacology & Toxicology
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-10-01
DOI
10.1186/s40360-021-00524-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)
- (2020) Manjunath Krishnappa et al. Cardiovascular Diabetology
- The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
- (2020) Divya P. Kumar et al. Scientific Reports
- Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study
- (2020) Omesh Goyal et al. Scientific Reports
- Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
- (2018) Zobair M. Younossi et al. HEPATOLOGY
- Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model”
- (2018) Yan-Lan Fang et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Pivotal Role of TNF-α in the Development and Progression of Nonalcoholic Fatty Liver Disease in a Murine Model
- (2017) Satomi Kakino et al. HORMONE AND METABOLIC RESEARCH
- A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease
- (2017) Zhonge Chen et al. Lipids in Health and Disease
- Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
- (2017) Mukul R. Jain et al. LIVER INTERNATIONAL
- The role of leptin in diabetes: metabolic effects
- (2016) Thomas H. Meek et al. DIABETOLOGIA
- Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression
- (2016) Enas A. Abd El-Haleim et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Molecular Pathogenesis of NASH
- (2016) Alessandra Caligiuri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
- (2016) Manoela Mota et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
- (2016) Elena Buzzetti et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD
- (2016) Barbara Gross et al. Nature Reviews Endocrinology
- Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis
- (2015) Stergios A. Polyzos et al. DIABETOLOGIA
- Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells
- (2015) Ling Chen et al. Oncotarget
- Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology
- (2014) Wen Liang et al. PLoS One
- TGF-β in wound healing: a review
- (2014) H.E. Douglas Journal of Wound Care
- Cytokines in alcoholic liver disease
- (2012) Leon An et al. ARCHIVES OF TOXICOLOGY
- Mitochondrial dysfunction in white adipose tissue
- (2012) Christine M. Kusminski et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Role of cytokines and chemokines in non-alcoholic fatty liver disease
- (2012) Vincent Braunersreuther WORLD JOURNAL OF GASTROENTEROLOGY
- Adiponectin reduces connective tissue growth factor in human hepatocytes which is already induced in non-fibrotic non-alcoholic steatohepatitis
- (2011) Roland Walter et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients
- (2011) Edith Koehler et al. LIVER INTERNATIONAL
- Role of serum adiponectin level in the development of liver cirrhosis in patients with hepatitis C virus
- (2010) Hatem Abdel Latif et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Monocyte chemoattractant protein-1 deficiency does not affect steatosis or inflammation in livers of mice fed a methionine–choline-deficient diet
- (2010) Karen M Kassel et al. LABORATORY INVESTIGATION
- Kupffer Cells Mediate Leptin-Induced Liver Fibrosis
- (2009) Jianhua Wang et al. GASTROENTEROLOGY
- Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients
- (2008) Y. Miyazaki et al. DIABETES OBESITY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now